Justin Bekelman, MD
Radiation Oncology · Philadelphia, PANPI 1912174608
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,195 of the $14,432 with a category attached, or 91.4%. AstraZeneca accounts for 60.2% of it on its own, with 4 other manufacturers making up the rest. Among radiation oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $534.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Astrazeneca UK Limited$5K
- Eli Lilly$680
- E.r. Squibb & Sons, L.L.C.$278
- Sanofi$258
Across 4 payments — averaging $118,880 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$476K
What the payments were for
- Consulting fees$13,19591%
- Speaking & faculty fees$2852%
- Travel & lodging$430%
- Food & beverage$6505%
- Charitable contribution$2582%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $8,686 |
| Astrazeneca UK Limited | 1 | $4,530 |
| Eli Lilly | 14 | $680 |
| E.r. Squibb & Sons, L.L.C. | 3 | $278 |
| Sanofi | 4 | $258 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,432 in reported general payments places this provider in the 90th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Philadelphia
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
- Sameera KumarPhiladelphia$29K
- Joshua MeyerPhiladelphia$25K
- Abigail BermanPhiladelphia$25K
- Michelle Alonso-BasantaPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.